Josep M Llovet#
| Membership Number: | 7616 |
| Membership type: | ORDINARY |
| Section: | BASIC AND CLINICAL TRANSLATIONAL SCIENCES |
| Elected: | 2026 |
| Main Country of Residence: | SPAIN |
| Homepage(s): | https://www.clinicbarcelona.org/ca/idibaps/arees-i-programes/cancer/recerca-translacional-en-oncologia-hepatica |
| ORCID: | 0000-0003-0547-2667 |
| Publication Link: | https://pubmed.ncbi.nlm.nih.gov/?term=nature%20and%20llovet%20jm |
Present and Previous Positions
- 2006 - present Full Professor of Research-ICREA. Director, Program of Translational Research in Cancer. Coordinator- Area #5 -Cancer-IDIBAPS; Group Leader- Translational research in Hepatic Oncology. Liver Unit. IDIBAPS-Hospital Clínic
- 2013 - present Full Professor of Medicine-Hepatic Oncology, 2020- & Director, Master in Translational Medicine, Faculty of Medicine, University of Barcelona
- 2009 - present Full Professor of Medicine (Academic Track, part time)
- 2005 - present Director Liver Cancer Program, The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai
- 2023 - present Editor-in-Chief, Journal of Hepatology Reports (Official Journal of EASL; IF: 9.5)
- 1989 - 1992 Board certified in Gastroenterology, and fellow in Hepatology (1993-1994). Hospital Germans Trias i Pujol. BCN.
- 1995 - 1997 Faculty at the Liver Unit-Hospital Clínic
- 1993 - 2003 Faculty of Gastroenterology, Area 8, BCN
- 1998 - 2003 Senior Investigator- BCLC group. IDIBAPS, Min. Ciencia Tecnología, BCN
- 2003 - 2004 Senior Scientist and Associate Professor of Medicine (2005-09), Division of Liver Diseases. Mt Sinai School of Medicine, New York, USA
Fields of Scholarship
- Emerging therapies in advanced HCC
- Neoajuvant/adjuvant therapies in early HCC
- Drivers of oncogenesis as targets for therapies in HCC
- Molecular characterization of human MASLD-HCC
- Molecular and immune classification of hepatocellular carcinoma (HCC)
- Molecular determinants of response to immunotherapies in HCC
- Immune-based combination regimens in intermediate HCC
- Artificial-intelligence-based approaches to predict response to immunotherapies in HCC
- Intratumoral and gut microbiome in HCC
Honours and Awards
- 1998 Extraordinary award of Doctoral Thesis
- 2009 AACR-Landon International Award, USA
- 2011 - 2013 President, International Liver Cancer Association (ILCA)
- 2012 International Hans Popper Award, Falk Foundation, Mainz, Germany
- 2013 Josep Trueta award, Barcelona
- 2015 Fellow, American Association for the Study of Liver Diseases, USA
- 2019 Leon Schiff State-of-The-Art lecture AASLD
- 2008, 2015, 2020 and 2025 ICREA scientific evaluation: Outstanding
- each year from 2014 to 2025 Top 1% cited investigator Clarivate Analytics
- Standford University world’s top scientist ranking: Top 0.013%; #4 in Spain
- 2021 - present Advisory Board of Nature Reviews Clinical Oncology
- 2023 - present Editor-in-Chief of the Journal of Hepatology Reports
- Coordinator & Principal investigator of two FP7 and Horizon Europe-Mission Cancer awards:
- FP7-2010-Health; HEPTROMIC
- Horizon-Miss-2023-Cancer-01; THRIVE
- Principal investigator in two National Institute of Health (NIH/NCI) RO1 awards: 2008: 1R01DK07698; 2023: 1R01CA273932-01A1
- 2024 HCC-Life award, 1st awardee for lifetime achievements in liver cancer research
